What you will be able to do

  • Explain the difference between pharmacodynamics (what the drug does to the body) and pharmacokinetics (what the body does to the drug), and why both are necessary for understanding drug effects.
  • Distinguish between agonists, partial agonists, and antagonists at a receptor, and explain the clinical significance of each (using opioids as a working example: morphine, buprenorphine, naloxone).
  • Define therapeutic index and explain why narrow therapeutic index drugs are more dangerous — connecting this to overdose risk and the fentanyl crisis.
  • Describe the four pharmacokinetic processes (absorption, distribution, metabolism, excretion) and explain how variation in each affects drug response.
  • Identify common drug interaction mechanisms (enzyme inhibition, enzyme induction, protein binding displacement) and explain why polypharmacy increases risk.
  • Articulate how pharmacological knowledge functions as harm reduction infrastructure — why understanding half-life, potency, and bioavailability makes rational risk management possible and why withholding this knowledge costs lives.

Prerequisites

  • No formal prerequisites. The introductory curriculum is self-contained.
  • Familiarity with basic cell biology (cell, receptor) is helpful but not required.

Reference documents

Scope

This skill covers pharmacological literacy — the conceptual foundation for understanding how drugs interact with living systems. It does not cover:

  • Prescribing or clinical pharmacotherapy (dosing, drug selection, monitoring)
  • Pharmacology of specific drug classes beyond those used as examples
  • Organic chemistry or molecular biology of drug-receptor binding
  • Herbal pharmacology or TCM formula composition

Verification

You have this skill if you can: (1) explain why buprenorphine is safer than methadone for opioid use disorder treatment using pharmacodynamic concepts; (2) explain why naloxone must be followed by emergency care using pharmacokinetic concepts; (3) identify a potential drug interaction mechanism given two drugs and their metabolic pathways; and (4) articulate why pharmacological literacy is a harm reduction issue, not merely a clinical one.